US 5,691,375 AGranted

Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor

AssigneeBristol-Myers Squibb Company

InventorsBruce D. Behounek, Mark E. McGovern, Adeoye Y. Olukotun

Life of this patent

Estimating the term…

Abstract

A method is provided for preventing or reducing the risk of onset of a cardiovascular event by administering an HMG CoA reductase inhibitor such as pravastatin, to a patient which has one or more risk factors for a coronary and/or cerebrovascular event such as hypercholesterolemia.

Claims6

Dependent claims

A method for preventing or reducing the risk of a cardiovascular event which is angina in a patient who has one or more risk factors for a cornary event, which comprises administering to a patient in need of such treatment a therapeutically effective amount of pravastatin.

Dependencies are inferred from the claim text.

Facts

Application: 08/448,211Filed 23 May 1995 · division
Priority: 18 Jan 1994
Granted: 25 Nov 1997
Term ends: Not estimatedThe source records don’t support an estimate.

Classification21 codes

A61K 31/662
Phosphorus compounds: phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
A61K 31/00
Medicinal preparations containing organic active ingredients
A61K 31/22
Of carboxylic acids: of acyclic acids, e.g. pravastatin
A61K 31/34
Having oxygen as the only ring hetero atom, e.g. fungichromin: having five-membered rings with one oxygen as the only ring hetero atom, e.g.…

Family

Serial182,471Parent of this division · filed 18 Jan 1994
US 5,691,375 AThis patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results